BPC-157 and Muscle: What the Published Research Says

Published August 22, 2026 · Artemis Labs

BPC-157 muscle research — BPC-157 is a peptide, a short chain of 15 amino acids, first identified as a fragment of a protein found in human stomach juice. It is studied for how muscle, tendon, and ligament tissue heals in animal models. The main muscle reference is a 2022 review that gathered animal studies across all three kinds of muscle in the body: the striated muscle attached to your skeleton, the smooth muscle inside organs and blood vessels, and heart muscle. A 2025 paper covered rat models in which a muscle was surgically detached from bone and reattached, and a 2026 review described the repair pathways researchers propose to explain these results. All of it is animal and laboratory work. No published human trial has tested whether BPC-157 does anything for muscle injury in people.

Key findings

• Staresinic 2022 (DOI: 10.3390/biomedicines10123221) reviewed BPC-157 findings across striated, smooth, and heart muscle models — the broadest single muscle reference in this literature.
• Matek 2025 (PMID 39861766) covered rat models of muscle-to-bone reattachment, the surgical setup used to study how muscle knits back to the skeleton.
• Matek 2026 (PMID 41754849) reviewed the mechanisms proposed across tendon, ligament, and muscle work, including a blood-vessel signalling pathway that runs through VEGF receptor 2.
• No published Phase II or Phase III human efficacy trial exists for muscle injury, or for any other use of BPC-157.

What is BPC-157?

A peptide is a short chain of amino acids, the same building blocks that make up proteins. BPC-157 is 15 of them in a row, first identified as part of a protein found in human gastric juice, the acidic fluid in the stomach.

One structural detail explains why the compound gets studied at all. It carries three proline amino acids in a row, a feature associated with resistance to the enzymes that normally chop small peptides apart. Published work reports it stays intact in human gastric juice for more than 24 hours, unusual for an unmodified peptide this size.

Laboratories order the BPC-157 research peptide for work across many tissues. Muscle sits alongside tendon research as one of the connective and contractile tissue areas where the animal literature is deepest.

What are the three kinds of muscle, and why does the split matter?

When a review says it covers “striated, smooth, and heart” muscle, it is naming the three tissue types anatomists recognise. They are built differently and do different jobs, so a finding in one does not automatically say anything about another.

Striated muscle is the muscle attached to bones — the kind that moves an arm or a leg. Under a microscope it shows regular light and dark bands, or striations, which is where the name comes from. It contracts under conscious control. This is the tissue people mean in everyday speech when they say “muscle.”

Smooth muscle lines hollow structures inside the body: the walls of the intestines, the bladder, and blood vessels. It has no banded appearance and it works without conscious control. It squeezes food along the gut and adjusts the width of blood vessels.

Heart muscle is its own category. It has bands like striated muscle but contracts on its own rhythm, continuously, without instruction.

The Staresinic 2022 review (DOI: 10.3390/biomedicines10123221) collected animal-model findings across all three. A review of this kind runs no new experiments. It assembles what separate studies have reported so later researchers can see where the evidence is thick and where it is thin. The heart muscle section of that review overlaps with a larger cardiovascular literature, which we cover separately on our BPC-157 heart research page.

What are muscle-to-bone reattachment models?

Matek 2025 (PMID 39861766) covered rat models of muscle-to-bone reattachment. The phrase describes a specific surgical setup. Researchers detach a muscle from the bone it anchors to, then reattach it, giving every animal in the study the same defined injury. They can then compare how that junction repairs itself with and without the compound under test.

This model exists because the place where muscle meets bone is one of the hardest junctions in the body to repair. It is a transition zone: soft, elastic muscle on one side, hard mineralised bone on the other, with a tendon in between. That is why it gets a research model of its own rather than being treated as ordinary muscle.

Our verified record lists the models Matek 2025 addressed but not a per-study effect size, so we do not put a number on the result here. What the paper establishes is that muscle-to-bone reattachment is an active BPC-157 research question in rats, not that anything has been demonstrated in a person.

How might BPC-157 affect muscle tissue?

Matek 2026 (PMID 41754849) reviewed the mechanisms researchers propose across tendon, ligament, and muscle models. Three come up repeatedly, and all three were measured in animals or in cells grown in a dish.

Blood-vessel signalling. Preclinical studies — meaning studies in animals and cells, not people — report that BPC-157 raised levels of VEGF receptor 2. That receptor sits on the cells lining blood vessels and receives the signal to grow new ones. The same studies report activity in two relay proteins further along the chain, Akt and eNOS. This pathway is the standard explanation offered for why new blood vessels are observed forming at injury sites in animal models. Damaged muscle needs oxygen and nutrients delivered to rebuild, so vessel supply is the mechanism researchers return to most.

Cell movement. Chang 2011 (DOI: 10.1152/japplphysiol.00945.2010) reported that tendon cells in culture grew outward, survived, and migrated faster when exposed to BPC-157, tracing this to the FAK–paxillin pathway. FAK and paxillin are proteins that let a cell grip its surroundings and haul itself along. Repair at a torn junction requires cells to travel into the damaged zone, so this pathway is read as relevant context for the muscle work — though it was measured in tendon cells, not muscle.

Growth-hormone receptors. Chang 2014 (DOI: 10.3390/molecules191119066) reported that tendon fibroblasts, the cells that build connective tissue, carried more receptors for growth hormone after exposure. Again: cultured cells, not living muscle.

For a wider view of how the preclinical evidence base fits together, including the first human-tissue mechanism data, see our 2026 preclinical foundation review.

What the research does not show

No published Phase II or Phase III human efficacy trial has tested BPC-157 for muscle injury or for anything else. Every efficacy statement anywhere in this literature is extrapolated from animal or tissue studies.

Three further limits apply specifically to the muscle evidence. First, “muscle” in this corpus covers three biologically different tissues, and a finding in smooth muscle of the gut tells you very little about the striated muscle of a leg. Second, much of the mechanism evidence is borrowed from tendon-cell culture work rather than measured in muscle itself. Third, effect sizes across the wider BPC-157 literature vary substantially with the animal model, the species, and the study design, so one rat result does not predict the size of anything elsewhere.

There is also no single defined receptor for this compound. It appears to act through several pathways at once, and no standard binding assay or agreed biomarker exists to say what a positive response even looks like.

One practical fact belongs here for anyone in sport. The World Anti-Doping Agency lists BPC-157 in Section S2 of its Prohibited List, banned at all times, in and out of competition. A tested athlete risks an anti-doping violation regardless of where the compound came from or why they used it.

Frequently asked questions

Has BPC-157 been tested in people with muscle injuries?

No. The muscle findings come from rat models and laboratory cell work. No published human efficacy trial exists for muscle injury or any other condition.

What does “striated muscle” mean?

It is the muscle attached to the skeleton, named for the light and dark bands visible under a microscope. It is the tissue most people picture when they hear the word muscle.

Is BPC-157 approved for muscle injury?

No. The FDA has not approved BPC-157 as a drug for any use. Its regulatory status is unsettled and under advisory committee review.

How does the muscle evidence compare with the tendon evidence?

Much of the tendon evidence comes from cells grown in culture with identified signalling pathways, while the muscle evidence leans on whole-animal surgical models and review articles. Our BPC-157 tendon research page covers that side.

References

1. Staresinic M, et al. (2022). Review of BPC-157 across striated, smooth, and heart muscle models. Biomedicines. DOI: 10.3390/biomedicines10123221
2. Matek D, et al. (2025). BPC-157 in rat muscle-to-bone reattachment models. PMID 39861766
3. Matek D, et al. (2026). Review of BPC-157 mechanisms in tendon, ligament, and muscle models. PMID 41754849
4. Chang CH, et al. (2011). Tendon-cell outgrowth, survival, and migration via FAK–paxillin signalling. Journal of Applied Physiology. DOI: 10.1152/japplphysiol.00945.2010
5. Chang CH, et al. (2014). Growth-hormone-receptor expression in tendon fibroblasts. Molecules. DOI: 10.3390/molecules191119066

Methodology: This page draws only on the verified BPC-157 research record compiled by Artemis Labs (citations last verified August 22, 2026); no claims beyond the cited sources.

All compounds sold by Artemis Labs are for laboratory research use only. Nothing on this page is medical advice, and no statement has been evaluated by the FDA.